Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 139

1.

Detrusor botulinum toxin A injection significantly decreased urinary tract infection in patients with traumatic spinal cord injury.

Jia C, Liao LM, Chen G, Sui Y.

Spinal Cord. 2013 Jun;51(6):487-90. doi: 10.1038/sc.2012.180. Epub 2013 Jan 29.

PMID:
23357928
[PubMed - indexed for MEDLINE]
2.

Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury.

Mehta S, Hill D, McIntyre A, Foley N, Hsieh J, Ethans K, Teasell RW, Loh E, Welk B, Wolfe D.

Arch Phys Med Rehabil. 2013 Aug;94(8):1473-81. doi: 10.1016/j.apmr.2013.04.011. Epub 2013 Apr 28. Review.

PMID:
23632286
[PubMed - indexed for MEDLINE]
3.

Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections.

Gamé X, Castel-Lacanal E, Bentaleb Y, Thiry-Escudié I, De Boissezon X, Malavaud B, Marque P, Rischmann P.

Eur Urol. 2008 Mar;53(3):613-8. Epub 2007 Aug 28.

PMID:
17804150
[PubMed - indexed for MEDLINE]
4.

Injections of Botulinum Toxin A into the detrusor to treat neurogenic detrusor overactivity secondary to spinal cord injury.

Chen G, Liao L.

Int Urol Nephrol. 2011 Sep;43(3):655-62. doi: 10.1007/s11255-010-9873-x. Epub 2010 Nov 26.

PMID:
21110094
[PubMed - indexed for MEDLINE]
5.

Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury and types of detrusor sphincter dyssynergia.

Chen CY, Liao CH, Kuo HC.

Spinal Cord. 2011 May;49(5):659-64. doi: 10.1038/sc.2010.179. Epub 2011 Jan 18.

PMID:
21243000
[PubMed - indexed for MEDLINE]
6.

Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.

Giannantoni A, Mearini E, Del Zingaro M, Porena M.

Eur Urol. 2009 Mar;55(3):705-11. doi: 10.1016/j.eururo.2008.08.048. Epub 2008 Sep 2.

PMID:
18814955
[PubMed - indexed for MEDLINE]
7.

Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results.

Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D.

J Urol. 2000 Sep;164(3 Pt 1):692-7.

PMID:
10953127
[PubMed - indexed for MEDLINE]
8.

OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.

Rovner E, Dmochowski R, Chapple C, Thompson C, Lam W, Haag-Molkenteller C.

Neurourol Urodyn. 2013 Nov;32(8):1109-15. doi: 10.1002/nau.22376. Epub 2013 Feb 6.

PMID:
23389824
[PubMed - indexed for MEDLINE]
Free Article
9.

Botulinum toxin type A for refractory neurogenic detrusor overactivity in spinal cord injured patients in Singapore.

Tow AM, Toh KL, Chan SP, Consigliere D.

Ann Acad Med Singapore. 2007 Jan;36(1):11-7.

PMID:
17285181
[PubMed - indexed for MEDLINE]
Free Article
10.

A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin.

Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P.

J Urol. 2005 Sep;174(3):984-9.

PMID:
16094019
[PubMed - indexed for MEDLINE]
11.

Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.

Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, Daniell G, Heesakkers J, Haag-Molkenteller C.

Eur Urol. 2011 Oct;60(4):742-50. doi: 10.1016/j.eururo.2011.07.002. Epub 2011 Jul 13.

PMID:
21798658
[PubMed - indexed for MEDLINE]
12.

Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.

Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, Brin MF, Jenkins B, Haag-Molkenteller C.

J Urol. 2012 Jun;187(6):2131-9. doi: 10.1016/j.juro.2012.01.125. Epub 2012 Apr 12.

PMID:
22503020
[PubMed - indexed for MEDLINE]
13.

Botulinum toxin A in the treatment of spinal cord injury patients with refractory neurogenic detrusor overactivity.

Alvares RA, Silva JA, Barboza AL, Monteiro RT.

Int Braz J Urol. 2010 Nov-Dec;36(6):732-7.

PMID:
21176280
[PubMed - indexed for MEDLINE]
Free Article
14.

Botulinum toxin type A for neurogenic detrusor overactivity due to spinal cord lesions in children: a retrospective study of seven cases.

Do Ngoc Thanh C, Audry G, Forin V.

J Pediatr Urol. 2009 Dec;5(6):430-6. doi: 10.1016/j.jpurol.2009.06.001. Epub 2009 Jul 3.

PMID:
19577520
[PubMed - indexed for MEDLINE]
15.

Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment.

Harris MA, Harding C, Fulford S, Whiteway J.

BJU Int. 2011 Apr;107(7):1165; author reply 1165. doi: 10.1111/j.1464-410X.2011.10216.x. No abstract available.

PMID:
21438980
[PubMed - indexed for MEDLINE]
16.

Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: a pilot study.

Krhut J, Samal V, Nemec D, Zvara P.

Spinal Cord. 2012 Dec;50(12):904-7. doi: 10.1038/sc.2012.76. Epub 2012 Jul 17.

PMID:
22801191
[PubMed - indexed for MEDLINE]
17.

Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity.

Conte A, Giannantoni A, Proietti S, Giovannozzi S, Fabbrini G, Rossi A, Porena M, Berardelli A.

Eur J Neurol. 2012 May;19(5):725-32. doi: 10.1111/j.1468-1331.2011.03618.x. Epub 2011 Dec 28.

PMID:
22212295
[PubMed - indexed for MEDLINE]
18.

OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology.

Ginsberg D, Cruz F, Herschorn S, Gousse A, Keppenne V, Aliotta P, Sievert KD, Brin MF, Jenkins B, Thompson C, Lam W, Heesakkers J, Haag-Molkenteller C.

Adv Ther. 2013 Sep;30(9):819-33. doi: 10.1007/s12325-013-0054-z. Epub 2013 Sep 27. Erratum in: Adv Ther. 2014 Feb;31(2):242.

PMID:
24072665
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment.

Mouttalib S, Khan S, Castel-Lacanal E, Guillotreau J, De Boissezon X, Malavaud B, Marque P, Rischmann P, Gamé X.

BJU Int. 2010 Dec;106(11):1677-80. doi: 10.1111/j.1464-410X.2010.09435.x.

PMID:
20590550
[PubMed - indexed for MEDLINE]
20.

Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study).

Tincello DG, Kenyon S, Abrams KR, Mayne C, Toozs-Hobson P, Taylor D, Slack M.

Eur Urol. 2012 Sep;62(3):507-14. doi: 10.1016/j.eururo.2011.12.056. Epub 2012 Jan 5.

PMID:
22236796
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk